Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma

Retinoids are an important component of neuroblastoma therapy at the stage of minimal residual disease, yet 40–50% of patients treated with 13‐cis‐retinoic acid (13‐cis‐RA) still relapse, indicating the need for more effective retinoid therapy. Vorinostat, or Suberoylanilide hydroxamic acid (SAHA),...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Oncol
Glavni autori: Cheung, Belamy B., Tan, Owen, Koach, Jessica, Liu, Bing, Shum, Michael S.Y., Carter, Daniel R., Sutton, Selina, Po'uha, Sela T., Chesler, Louis, Haber, Michelle, Norris, Murray D., Kavallaris, Maria, Liu, Tao, O'Neill, Geraldine M., Marshall, Glenn M.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Research Papers
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528804/
https://ncbi.nlm.nih.gov/pubmed/25963741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.04.005
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items